Targeting CDK9 for the Treatment of Glioblastoma.

Ranjan, Alice; Pang, Ying; Butler, Madison; Merchant, Mythili; Kim, Olga; Yu, Guangyang; Su, Yu-Ting; Gilbert, Mark R; Levens, David; Wu, Jing

Ranjan, Alice; Pang, Ying; Butler, Madison; Merchant, Mythili; Kim, Olga; Yu, Guangyang; Su, Yu-Ting; Gilbert, Mark R; Levens, David; Wu, Jing.

Afiliación

Ranjan A; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Pang Y; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Butler M; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Merchant M; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Kim O; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Yu G; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Su YT; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Gilbert MR; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Levens D; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Wu J; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Cancers (Basel) ; 13(12)2021 Jun 18.

Article en En | MEDLINE | ID: mdl-34207158

Palabras clave

CDK9 inhibitor; clinical trial; glioblastoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google